Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

207P - Diagnostic value of 18F-FDG PET-CT and MTV as a prognostic factor in patients with multifocal hepatocellular carcinoma T2-3N0M0, BCLC-B in the «downstaging» or «bridge» mode treatment to liver transplantation and liver transplantation planning

Date

27 Jun 2024

Session

Poster Display session

Presenters

Yuliya Yermakovich-Sauchuk

Citation

Annals of Oncology (2024) 35 (suppl_1): S75-S93. 10.1016/annonc/annonc1478

Authors

Y. Yermakovich-Sauchuk1, A. Bialiutsin2, A. Shcherba3, D. Liovina3

Author affiliations

  • 1 Minsk City Clinical Oncology Centre, Minsk/BY
  • 2 State Institution N. N. Alexandrov National Cancer Centre of Belarus, Lesnoy - Minsk District/BY
  • 3 Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology, Minsk/BY

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 207P

Background

PET-CT is a surrogate marker of microvascular invasion and G3 differentiation. In patients with Hepatocellular carcinoma outside the Milan and UCSF criteria for liver transplantation (LT), 18-FDG accumulation is considered a risk factor if «downstaging» criteria are met or a contraindication in the case of a «sawtooth» (unstable) response curve according to mRECIST and AFP/PIVKA. The effectiveness of LT in patients with positive PET results is much lower than in patients with negative PET results. Lu RC et al. indicates that the rate of HCC recurrence after LT in patients with negative PET results is 3,6% and 54,3% in patients with positive PET results (p<0,001). 5-year disease-free survival of patients with PET-negative tumors comparable to that of the Milan criteria (86,2%), and outside the Milan criteria (81%), but it is significantly lower after LT of PET-positive HCC – 21%.

Methods

26 patients (HCC T2-3N0M0, BCLC-B) were performed baseline PET-CT examination (before «downstaging» therapy): 12 patients in the group of positive clinical outcome, 14 patients in the group of negative clinical outcome. 10 patients in the group of positive clinical outcome underwent liver transplantation. Nodes with SUVmax and SULpeak above the reference value of average accumulation in the mediastinal blood pool, calculated by the formula: 2*Mean + 2*SD, were considered as highly metabolically active.

Results

A statistically significant difference in the medians of Metabolic tumor volumes (MTV) with a fixed absolute threshold SUVmax=2,5 (Fixed Absolute MTV 2,5) was revealed. The median of Fixed Absolute MTV 2,5 in the group of negative clinical outcome was 199,06 ml (0;945,60), in the group of positive clinical outcome (underwent liver transplantation) was 10,15 ml (3,61;27,66) (p=0,03).

Conclusions

18F-FDG PET-CT and MTV is a strong independent prognostic factor in the evaluation of patients with HCC at high risk of early progression. This may be useful as a risk and prognostic factor in liver transplantation planning.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.